Cryptococcal meningitis is one of the most common opportunistic infections among HIV/AIDS patients, estimating more than 220,000 cases and 181,000 deaths worldwide each year.1 Early detection and treatment of infection are key to reducing the mortality associated with this disease.
This test is a direct immunoenzymatic, sandwich microplate assay and has been considered the most sensitive and specific EIA for the detection of cryptococcal antigen.
1) Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873-881.
|Competitor EIA||Positive % Agreement||Negative % Agreement|
Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid.
Hansen J, Slechta ES, Gates-Hollingsworth MA, Neary B, Barker AP, Bauman S, Kozel TR, Hanson KE. Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol. 2013 Jan;20(1):52-5.
Comparison of Four Assays for the Detection of Cryptococcal Antigen
Binnicker MJ, Jespersen DJ, Bestrom JE, Rollins LO. Comparison of four assays for the detection of cryptococcal antigen. Clin Vaccine Immunol. 2012;19(12):1988–1990.
|Cryptococcus Antigen EIA||192 tests||CRY101|